Ratg denied as not FDA-approved for this use by Humana?

Humana Medicare Advantage plans must follow CMS coverage guidelines, and services must be provided according to Medicare coverage guidelines established by the Centers for Medicare & Medicaid Services (CMS), under which all medical care, services, supplies and equipment must be medically necessary . Under CMS NCD 260.7, the FDA has approved lymphocyte immune globulin, anti-thymocyte globulin (equine) for the management of allograft rejection episodes in renal transplantation, it is covered under Medicare when used for this purpose, and other forms of lymphocyte globulin preparation that the FDA approves for this indication may be covered . The FDA-labeled indication for rabbit ATG is that Thymoglobulin (anti-thymocyte globulin, rabbit) is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression , with the approved regimen being 1.5 mg/kg of body weight administered daily for 4 to 7 days . Per FDA labeling, Thymoglobulin is contraindicated in patients with a history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or who have active acute or chronic infections that contraindicate any additional immunosuppression , and dose reductions are required when the WBC count is between 2,000 and 3,000 cells/mm3 or if the platelet count is between 50,000 and 75,000 cells/mm3 . Humana requires prior authorization through its transplant network: preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300 or by phone at 866-421-5663 , and Humana MA may apply step therapy requirements for some drugs under its Part B Step Therapy Preferred Drug List. To prevent disruption of care, Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment, though Humana may review services furnished during an active course of treatment against permissible coverage criteria when determining payment .

- For kidney transplant rejection prophylaxis or treatment, the request aligns squarely with the FDA label: Thymoglobulin is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression , and the drug is indicated for management of allograft rejection episodes in renal transplantation and is covered under Medicare when used for this purpose per CMS NCD 260.7 - KDIGO clinical practice guidelines support ATG-based induction in kidney transplant recipients, particularly those at high immunologic risk; anti-thymocyte globulin is a highly efficient induction agent that can prevent acute rejection and delayed graft function and is widely used for biopsy-confirmed acute rejection reversal and steroid-resistant rejection - For steroid-resistant or vascular rejection, ATG is the guideline-endorsed standard: ATG is a pivotal immunosuppressive therapy utilized in the management of T-cell-mediated rejection and steroid-resistant rejection among renal transplant recipients ; an IL-2 receptor antagonist (basiliximab) is not an appropriate substitute for treatment of established rejection, so step-therapy requirements should be waived - Dosing requested matches the FDA-approved regimen of 1.5 mg/kg of body weight administered daily for 4 to 7 days for induction, or a 7 to 14 day course of daily infusion of 1.5 mg/kg of Thymoglobulin for treatment of acute rejection, consistent with the package insert and LiverTox/NIH summaries - Thymoglobulin is preferred over equine ATG in high-risk recipients: multiple studies have indicated that thymoglobulin is favored in comparison to other induction agents for patients who have increased risk of developing post-transplant complications, such as elderly patients, patients undergoing a repeat transplantation, and patients in which minimization of use of steroids or CNIs post-operation is recommended — relevant for the Medicare Advantage population - Humana's own policy framework grants continuity-of-care protection: Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment , and members can request expedited exception reviews for step therapy prior authorization requests - Contraindication-based denials should be rebutted with documentation that the patient has no history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or active acute or chronic infections that contraindicate any additional immunosuppression , satisfying the only FDA-labeled contraindications

## Why Humana Denied rATG as "Not FDA-Approved" — and How to Appeal

Rabbit anti-thymocyte globulin (rATG) holds FDA approval for specific indications. A "not FDA-approved" denial from Humana typically does not mean the drug itself lacks FDA approval in general — it usually means one of the following: the specific indication for which it is being prescribed is not in the FDA-approved labeling (i.e., it is an off-label use); the prescribing information does not cover the patient population, setting, or protocol described in the authorization request; or Humana's internal medical policy does not recognize the submitted indication as a covered use regardless of FDA approval status.

This distinction is critical: off-label use of an FDA-approved drug is a standard, legal, and often evidence-supported practice in medicine. Humana's coverage policies typically address off-label use through specific criteria, including recognition in authoritative medical compendia, which is a distinct pathway from the FDA-approval question.

## Why This Denial Is Appealable

If rATG is FDA-approved for any indication, a blanket "not FDA-approved" denial may rest on a mischaracterization of the drug's regulatory status. If the use is off-label, the appeal should pivot to demonstrating compendia listing, professional society guideline support, and the clinical standard of care — all of which are grounds for coverage under most Humana policies and under applicable federal and state law.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your Explanation of Benefits (EOB), typically 180 days from the denial date.
• ACA §2719 / external review: After a final internal denial, you are entitled to independent external review by a certified IRO. The standard window is approximately four months from the final internal denial. Expedited review (72-hour decision) is available for urgent situations.
• ERISA §503: Employer-plan members are entitled to full disclosure of the policy basis for the denial and a full-and-fair review.

## Concrete Appeal Steps

1. Obtain the denial letter and Humana's medical policy, confirming whether the denial is based on the drug lacking FDA approval generally or on the specific indication being off-label. 2. Pull the FDA prescribing information (label) for rATG and identify the approved indications. If your use is on-label, this alone rebuts the denial. 3. If your use is off-label, check whether it is listed in a recognized medical compendium (e.g., Micromedex/Drugdex, NCCN Drugs & Biologics Compendium). Compendium listings are often contractually binding on Humana. 4. Ask your treating specialist to write a medical-necessity letter addressing FDA status, any compendium listing, and applicable professional society guideline support. 5. File the internal appeal before the EOB deadline. 6. If denied internally, file for external review.

## Documentation to Gather

• FDA prescribing information: The current FDA label for rATG, with approved indications highlighted and the off-label use section (if applicable) clearly identified.
• Compendium listing: A printout from a recognized medical compendium confirming the listing of rATG for your specific indication, if applicable.
• Prescriber medical-necessity letter: A letter from your transplant physician or treating specialist addressing the FDA-approval and off-label questions directly, explaining the clinical evidence base, and citing the applicable professional society guideline organization by name.
• Diagnosis and clinical records: Chart notes confirming your diagnosis and the specific clinical indication for which rATG was prescribed.
• Professional society guideline citation: Reference to the guideline organization (by name) that supports rATG use in your specific clinical situation.

## Criteria-Mapping Structure

Obtain Humana's coverage policy for rATG and identify the exact regulatory and evidentiary criteria applied. Build a two-column table: left column lists each criterion (FDA approval, compendia recognition, guideline support, peer review); right column cites the FDA label page, compendium entry, or clinician letter paragraph that satisfies it. A structured response that directly addresses the regulatory question — distinguishing drug-level FDA approval from indication-level coverage — is the most effective format for this denial type.